Promising drug targets rare childhood tumors in phase 2 trial

NCT ID NCT02114229

First seen Mar 22, 2026 · Last updated Apr 28, 2026 · Updated 3 times

Summary

This study tests a drug called alisertib in children and young adults under 22 with rare, aggressive tumors of the brain (AT/RT) or kidney (MRT). For those whose cancer has returned, alisertib is given alone. For newly diagnosed patients, it is combined with chemotherapy and sometimes radiation. The goal is to see if the drug can shrink tumors or stop them from growing, and to find the best way to use it in these hard-to-treat cancers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATYPICAL TERATOID RHABDOID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Children's Healthcare of Atlanta

    Atlanta, Georgia, 30322, United States

  • Children's Hospital Colorado

    Aurora, Colorado, 80045, United States

  • Children's Hospital and Clinics of Minnesota

    Minneapolis, Minnesota, 55102, United States

  • Children's National Medical Center

    Washington D.C., District of Columbia, 20010, United States

  • Lucille Packard Children's Hospital at Stanford University Medical Center

    Palo Alto, California, 94304, United States

  • Rady Children's Hospital

    San Diego, California, 92123, United States

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

  • Texas Children's Hospital

    Houston, Texas, 77030, United States

  • UF Cancer Center at Orlando Health

    Orlando, Florida, 32806, United States

Conditions

Explore the condition pages connected to this study.